Abstract: A method for manufacturing a blade with a first portion and a second portion, the method includes forming the first portion that includes forming a model of the first portion from removable material, forming a first shell mould from the model of the first portion, and forming the single-crystal or columnar first portion m a first metal alloy in the first shell mould from a single-crystal seed, and forming the second portion in which the second portion is formed on the first portion, and in which the first portion and the second portion are made from different materials, the second portion being polycrystalline and formed from a second metal alloy. The blade includes a single-crystal or columnar first portion made from a first metal alloy and a polycrystalline second portion made from the second metal alloy different from the first metal alloy.

Abstract: A method for manufacturing a blade with a first portion and a second portion, the method includes forming the first portion that includes forming a model of the first portion from removable material, forming a first shell mould from the model of the first portion, and forming the single-crystal or columnar first portion m a first metal alloy in the first shell mould from a single-crystal seed, and forming the second portion in which the second portion is formed on the first portion, and in which the first portion and the second portion are made from different materials, the second portion being polycrystalline and formed from a second metal alloy. The blade includes a single-crystal or columnar first portion made from a first metal alloy and a polycrystalline second portion made from the second metal alloy different from the first metal alloy.

Abstract: The present invention provides methods for treating diseases and disorders that are associated with elevated levels of lipids and lipoproteins. The methods of the present invention comprise administering to a high cardiovascular risk patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P or alirocumab. The methods of the present invention are useful for treating high cardiovascular risk patients with hypercholesterolemia and elevated levels of other atherogenic lipoproteins that are not adequately controlled by maximum tolerated dose statin therapy. In particular, the methods of the present invention are useful for reducing cardiovascular risk and lowering atherogenic lipoproteins in high cardiovascular risk patients within 12 months following an acute coronary syndrome event despite a maximum tolerated dose statin therapy.

Abstract: The disclosure provides iron-based metallurgical compositions comprising iron and alloying elements of about (0.01) to about (0.65) wt %, based on the weight of the composition, of carbon; about (1) to about (2.0) wt %, based on the weight of the composition, of molybdenum; about (0.25) to about (2.0) wt %, based on the weight of the composition, of manganese; about (0.25) to about (2.0) wt %, based on the weight of the composition, of silicon; and about (0.05) to about (0.6) wt %, based on the weight of the composition, of vanadium. In some embodiments, the iron-based metallurgical composition is a powder metallurgical composition.

Abstract: Improved treatments of inflammation caused by HIV using cannabinoids. An exemplary treatment according to the present invention includes administration of an oral solution having a THC+CBD formulation in a 1:1 ratio.

Abstract: The present invention provides methods for treating diseases and disorders that are associated with elevated levels of lipids and lipoproteins. The methods of the present invention comprise administering to a high cardiovascular risk patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P or alirocumab. The methods of the present invention are useful for treating high cardiovascular risk patients with hypercholesterolemia and elevated levels of other atherogenic lipoproteins that are not adequately controlled by maximum tolerated dose statin therapy. In particular, the methods of the present invention are useful for reducing cardiovascular risk and lowering atherogenic lipoproteins in high cardiovascular risk patients within 12 months following an acute coronary syndrome event despite a maximum tolerated dose statin therapy.

Abstract: The invention relates to system conceived and designed to identify pieces of fruit, especially citrus fruits, affected by any amount of rot and to determine the automatic expulsion of these pieces from the conveyor moving them through the installation. The system comprises illuminating the fruits with UV-A band light in a computer vision unit, and capturing images of the illuminated fruits by means of a camera to send them to a general control member in order to detect fluorescences associated to the rot effect. The identified fruit is automatically expelled from the conveyor in an expulsion unit, the position of the defective fruit being determined with the aid of an encoder associated to the conveyor. The general control member is a PC type computer, equipped with specific application software.

Abstract: A method for determining an increased risk of mortality or of a cardiac and/or vascular event in a patient, comprising: determining the sPLA2 activity of said patient, comparing said activity to a predetermined value, a higher sPLA2 activity of the patient as compared to the predetermined value being indicative of an increased risk of mortality or of a cardiac and/or vascular event.

Abstract: The present invention provides methods for treating diseases and disorders that are associated with elevated levels of lipids and lipoproteins. The methods of the present invention comprise administering to a high cardiovascular risk patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P or alirocumab. The methods of the present invention are useful for treating high cardiovascular risk patients with hypercholesterolemia and elevated levels of other atherogenic lipoproteins that are not adequately controlled by maximum tolerated dose statin therapy. In particular, the methods of the present invention are useful for reducing cardiovascular risk and lowering atherogenic lipoproteins in high cardiovascular risk patients within 12 months following an acute coronary syndrome event despite a maximum tolerated dose statin therapy.

Abstract: The invention relates to system conceived and designed to identify pieces of fruit, especially citrus fruits, affected by any amount of rot and to determine the automatic expulsion of these pieces from the conveyor moving them through the installation. The system comprises illuminating the fruits with UV-A band light in a computer vision unit, and capturing images of the illuminated fruits by means of a camera to send them to a general control member in order to detect fluorescences associated to the rot effect. The identified fruit is automatically expelled from the conveyor in an expulsion unit, the position of the defective fruit being determined with the aid of an encoder associated to the conveyor. The general control member is a PC type computer, equipped with specific application software.

Abstract: This method allows direct 3D tailoring of a garment. It includes the steps of 3D-digitizing of a human body, of tracing a 3D mesh representing the garment over the 3D image of the body, and of modifying selectively the distance between the mesh and the body so as to visualize immediately in 3D how the garment fits to the body.

Abstract: A support apparatus for supporting components of a dental material includes two individual bottles each capable of receiving therein a component which can be shaken. Each individual bottle has a coding associated therewith and a cover has cover regions with respective codings corresponding to the bottle coding. A mixing base has a pair of recesses each with individual coding corresponding to the coding of a respective one of the individual bottles, whereby each respective bottle has a respective cover region and a respective recess of the mixing base associated therewith and identifiable as associated therewith by virtue of the corresponding coding thereon. The individual bottles collectively comprise a bottle unit and are closeable by a common cover.

Abstract: A support apparatus for supporting components of a dental material includes two individual bottles each capable of receiving therein a component which can be shaken. Each individual bottle has a coding associated therewith and a cover has cover regions with respective codings corresponding to the bottle coding. A mixing base has a pair of recesses each with individual coding corresponding to the coding of a respective one of the individual bottles, whereby each respective bottle has a respective cover region and a respective recess of the mixing base associated therewith and identifiable as associated therewith by virtue of the corresponding coding thereon. The individual bottles collectively comprise a bottle unit and are closeable by a common cover.

Abstract: The method includes the steps of:

Abstract: A method for treating restenosis by gene therapy is disclosed, said method comprising delivering a recombinant suicide-gene-containing adenovirus.